- Home
- CYRX vs ATYR Comparison
CYRX vs ATYR Comparison
Compare CYRX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- ATYR
- Stock Information
- Founded
- CYRX 1999
- ATYR 2005
- Country
- CYRX United States
- ATYR United States
- Employees
- CYRX N/A
- ATYR N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYRX Health Care
- ATYR Health Care
- Exchange
- CYRX Nasdaq
- ATYR Nasdaq
- Market Cap
- CYRX 438.7M
- ATYR 451.3M
- IPO Year
- CYRX N/A
- ATYR 2015
- Fundamental
- Price
- CYRX $8.77
- ATYR $5.17
- Analyst Decision
- CYRX Strong Buy
- ATYR Strong Buy
- Analyst Count
- CYRX 10
- ATYR 5
- Target Price
- CYRX $11.70
- ATYR $23.25
- AVG Volume (30 Days)
- CYRX 1.1M
- ATYR 3.9M
- Earning Date
- CYRX 08-05-2025
- ATYR 08-07-2025
- Dividend Yield
- CYRX N/A
- ATYR N/A
- EPS Growth
- CYRX N/A
- ATYR N/A
- EPS
- CYRX 1.35
- ATYR N/A
- Revenue
- CYRX $237,879,000.00
- ATYR N/A
- Revenue This Year
- CYRX N/A
- ATYR $478.72
- Revenue Next Year
- CYRX $9.08
- ATYR $1,899.26
- P/E Ratio
- CYRX $6.49
- ATYR N/A
- Revenue Growth
- CYRX 24.93
- ATYR N/A
- 52 Week Low
- CYRX $4.58
- ATYR $1.67
- 52 Week High
- CYRX $9.48
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CYRX 57.54
- ATYR 50.06
- Support Level
- CYRX $8.39
- ATYR $5.03
- Resistance Level
- CYRX $9.05
- ATYR $5.52
- Average True Range (ATR)
- CYRX 0.54
- ATYR 0.31
- MACD
- CYRX 0.00
- ATYR 0.02
- Stochastic Oscillator
- CYRX 69.23
- ATYR 50.64
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.